Intervention not reported
28‐day all‐cause mortality · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention probably leads to lower 28‐day all‐cause mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Thrombotic events up to day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in thrombotic events up to day 45 (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events up to day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in serious adverse events up to day 45 (low certainty).
1 finding from 1 review
Intervention not reported
Worsening up to day 28: participants with new need for invasive mechanical ventilation or death · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in worsening up to day 28: participants with new need for invasive… (moderate certainty).
1 finding from 1 review
Intervention not reported
Improvement up to day 28: participants discharged alive · hospitalised adults with COVID‐19 (moderate to severe disease)
The intervention showed no clear difference in improvement up to day 28: participants discharged alive (moderate certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality at day 45 · non‐hospitalised adults with mild COVID‐19
The intervention showed no clear difference in all‐cause mortality at day 45 (low certainty).
1 finding from 1 review
Intervention not reported
Admission to hospital or death up to day 45 · non‐hospitalised adults with mild COVID‐19
It is very uncertain whether the intervention changes admission to hospital or death up to day 45 (very low certainty).
1 finding from 1 review
Surgical site infection · adult patients with incarcerated or strangulated groin hernia
It is very uncertain whether summary of findings table ‐ mesh repair changes surgical site infections within 30 days of repair compared with non‐mesh repair (very low certainty).
1 finding from 1 review
Mortality within 30 days of repair · adult patients with incarcerated or strangulated groin hernia
It is very uncertain whether summary of findings table ‐ mesh repair changes mortality within 30 days of repair compared with non‐mesh repair (very low certainty).
1 finding from 1 review
Complications classified by the Clavien‐Dindo Classification within 30 days of repair · adult patients with incarcerated or strangulated groin hernia
1 finding from 1 review
Clinical recurrence or reoperation for recurrence within 30 days of repair · adult patients with incarcerated or strangulated groin hernia
1 finding from 1 review
Reoperation due to complications (e.g. infection, seroma, bleeding) within 30 days of repair · adult patients with incarcerated or strangulated groin hernia
1 finding from 1 review
Mesh removal within 30 days of repair · adult patients with incarcerated or strangulated groin hernia
1 finding from 1 review
All‐cause mortality at day 28 · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in all‐cause mortality at day 28 compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.79 [0.43, 1.44]
Studies not reported
Low
Clinical improvement: participants discharged from hospital ‐ not reported · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in improvement of clinical status (number of participants discharged… compared with saline placebo (low certainty).
1 finding from 1 review
Adverse events: all grades · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
1 finding from 1 review
OR 4
3 participants
GRADE not reported
Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).
1 finding from 1 review
Worsening of clinical status at day 28 (data only available for clinical status worsened on day 7) · individuals with moderate or severe COVID‐19
It is very uncertain whether hyperimmune immunoglobulin from human plasma changes worsening of clinical status at day 28 (data only available for… compared with saline placebo (very low certainty).
1 finding from 1 review
RR 0.85 [0.58, 1.23]
Studies not reported
Very low
Adverse events: all grades · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in adverse events of any grade up to 28 days (data only available for… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.98 [0.81, 1.18]
Studies not reported
Low